HNSPF (Hansoh Pharmaceutical Group Co) Beneish M-Score: -2.66 (As of Jul. 03, 2026)


HNSPF Hansoh Pharmaceutical Group Co Ltd HNSPF
90 GF Score
Price $3.83
GF Value $3.00
Valuation Modestly Overvalued
View Full Analysis

What is Hansoh Pharmaceutical Group Co Beneish M-Score?

Hansoh Pharmaceutical Group Co HNSPF 90 Beneish M-Score is -2.66 as of Jul. 03, 2026. GuruFocus rates HNSPF with a GF Score™ of 90/100 and a GF Value™ of $3.00 (Modestly Overvalued). Among 909 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks better than 64.36% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.66 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Hansoh Pharmaceutical Group Co's Beneish M-Score or its related term are showing as below:

HNSPF' s Beneish M-Score Range Over the Past 10 Years
Min: -3.04   Med: -2.43   Max: 1.02
Current: -2.66

During the past 10 years, the highest Beneish M-Score of Hansoh Pharmaceutical Group Co was 1.02. The lowest was -3.04. And the median was -2.43.


Hansoh Pharmaceutical Group Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Hansoh Pharmaceutical Group Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansoh Pharmaceutical Group Co Beneish M-Score Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 -2.38 -2.48 -2.15 -2.66

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.48 0.00 -2.15 0.00 -2.66

HNSPF vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's Beneish M-Score falls into.


HNSPF
90GF Score
Hansoh Pharmaceutical Group Co Ltd HNSPF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansoh Pharmaceutical Group Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Hansoh Pharmaceutical Group Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7864+0.528 * 1.0106+0.404 * 0.9505+0.892 * 1.2671+0.115 * 1.0026
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8569+4.679 * -0.029643-0.327 * 1.2789
=-2.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was $437 Mil.
Revenue was $2,134 Mil.
Gross Profit was $1,921 Mil.
Total Current Assets was $5,048 Mil.
Total Assets was $5,665 Mil.
Property, Plant and Equipment(Net PPE) was $456 Mil.
Depreciation, Depletion and Amortization(DDA) was $56 Mil.
Selling, General, & Admin. Expense(SGA) was $672 Mil.
Total Current Liabilities was $624 Mil.
Long-Term Debt & Capital Lease Obligation was $7 Mil.
Net Income was $789 Mil.
Gross Profit was $0 Mil.
Cash Flow from Operations was $957 Mil.
Total Receivables was $439 Mil.
Revenue was $1,684 Mil.
Gross Profit was $1,532 Mil.
Total Current Assets was $3,769 Mil.
Total Assets was $4,348 Mil.
Property, Plant and Equipment(Net PPE) was $449 Mil.
Depreciation, Depletion and Amortization(DDA) was $55 Mil.
Selling, General, & Admin. Expense(SGA) was $619 Mil.
Total Current Liabilities was $370 Mil.
Long-Term Debt & Capital Lease Obligation was $8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(436.96 / 2133.735) / (438.514 / 1684.016)
=0.204786 / 0.260398
=0.7864

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1532.189 / 1684.016) / (1921.067 / 2133.735)
=0.909842 / 0.900331
=1.0106

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (5048.18 + 455.741) / 5665.088) / (1 - (3769.115 + 448.925) / 4348.188)
=0.028449 / 0.029932
=0.9505

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2133.735 / 1684.016
=1.2671

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(55.125 / (55.125 + 448.925)) / (55.801 / (55.801 + 455.741))
=0.109364 / 0.109084
=1.0026

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(672.351 / 2133.735) / (619.225 / 1684.016)
=0.315105 / 0.367707
=0.8569

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((6.762 + 623.997) / 5665.088) / ((8.38 + 370.187) / 4348.188)
=0.111341 / 0.087063
=1.2789

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(788.769 - 0 - 956.702) / 5665.088
=-0.029643

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Hansoh Pharmaceutical Group Co has a M-score of -2.66 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.66 mean?
Hansoh Pharmaceutical Group Co (HNSPF) has a Beneish M-Score of -2.66 as of Jul. 03, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Hansoh Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #324 out of 909 companies in the Drug Manufacturers industry, placing it in the top 35.6%.
Is Hansoh Pharmaceutical Group Co's Beneish M-Score too high?
Hansoh Pharmaceutical Group Co's current Beneish M-Score is -2.66. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #324 out of 909 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #324 out of 909 companies for Beneish M-Score. This puts Hansoh Pharmaceutical Group Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Hansoh Pharmaceutical Group Co and its competitors. Hansoh Pharmaceutical Group Co's current Beneish M-Score is -2.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.00, compared to a current price of $3.83 — trading 27.5% above its estimated fair value. The current Beneish M-Score is -2.66. Hansoh Pharmaceutical Group Co's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current Beneish M-Score is -2.66 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued. The current stock price of $3.83 is trading 27.5% above its estimated GF Value™ of $3.00. GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.

Key valuation signals for HNSPF:

  • Beneish M-Score: -2.66
  • GF Value™: $3.00 vs. price of $3.83 (27.5% above fair value)
  • GF Score™: 90/100

No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hansoh Pharmaceutical Group Co Business Description

Address No. 287 Xiangke Road, Pudong New Area, Shanghai, CHN
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
90GF Score

Get the complete analysis for HNSPF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.83
Price
$3.00
GF Value